Key Highlights: 

• Understanding the terminology of treatment adherence: compliance, adherence, concordance 
• Factors affecting adherence in epilepsy patients: seizure type, medication regime, patient characteristics. 
• Strategies for improving adherence: doctor-patient relationship, psychosocial factors, educational interventions, medication tools and technologies. 
• Research on antiepileptic therapy adherence: study designs, materials and methods, results, implications for practice, and future research. 
• Importance of treatment adherence for effective epilepsy management. 

Introduction 

Epilepsy affects millions worldwide. It causes repeated seizures of varying severity. Proper management of epilepsy centers on sticking to treatment plans. These mostly consist of antiepileptic drugs (AEDs). When patients follow their set management regimen, their quality of life improves, and epilepsy-related complications are avoided. This article explores treatment adherence in epilepsy. We’ll look into factors that influence it and discuss strategies to improve it. We’ll also touch on research findings about it. Lastly, we will answer some frequently asked questions regarding this topic.  

Understanding Treatment Adherence 

Before we focus on adherence in epilepsy, we should grasp what it means and how it’s measured. Adherence is how well a person follows advice from healthcare professionals. This could be medication, diet, or lifestyle changes. 

Terminology 

Three keywords are linked to treatment adherence: compliance, adherence, and concordance. Compliance sees the patient following healthcare advice passively. Adherence puts the patient in control of their health management. Concordance is about both patient and provider making joint decisions, with open conversation and shared duty. 

Measuring Adherence 

To check adherence isn’t easy. Many methods exist. Direct ones include watching drug intake and monitoring blood levels. Indirect methods range from self-reporting to using adherence questionnaires. Each method has its pros and cons. So, the context of the patient and management regimen is critical in choosing how to measure adherence. 

Factors Affecting Adherence 

Different things can sway how well epilepsy treatment is adhered to. Seizure type, medication regime, and patient characteristics like age, gender, and education level are some. Patient beliefs about epilepsy and its treatment matter too. Being aware of these factors aids healthcare providers in crafting the right approach and pinpointing likely hurdles to adherence. 

Challenges in Assessing and Ensuring Adherence 

The main issue in checking and securing adherence to epilepsy treatment plans is the intricate interaction between personal factors, social surroundings, and the therapy’s effectiveness. Addressing this calls for an approach that’s bespoke to each patient’s needs and circumstances. 

Treatment Adherence in Epilepsy 

To value the importance of adherence in epilepsy treatment, we have to look at epilepsy prevalence, its management, and the fallout of non-adherence. 

1. Prevalence of Epilepsy 

Around 50 million people have epilepsy worldwide. About 10% of all people will have a seizure at least once. Epilepsy is marked by repeated seizures caused by unusual brain electrical activity. 

2. Overview of Antiepileptic Drugs (AEDs)  

AEDs are the key therapeutic modality for epilepsy. They manage seizure frequency and severity. How a person’s epilepsy is managed depends on seizure type, patient age, and more. Side effects or interactions with other medicines might also affect which AEDs are given. 

3. Investigating the Extent of Non-Adherence 

Not sticking to epilepsy treatment is a big worry. Adherence rates in studies range from 30% to 70%. Many factors can lead to non-adherence. These include forgetting, misunderstanding instructions, fear of side effects, fear of dependency, and lack of knowledge on the disease or its management. 

4. Quality of Life and Epilepsy 

Following AEDs not only decreases seizure frequency and severity. It also greatly affects patient life quality. Seizures can cause injury, social stigma, and limit daily activities. AED side effects can worsen a patient’s well-being. Thus, optimal adherence may boost quality of life and lessen epilepsy’s negative effects. 

Strategies for Improving Treatment Adherence 

With the difficulty of ensuring adherence to epilepsy treatment, healthcare providers must use diverse methods to increase patient dedication to their medication regimen and eventually improve their well-being.  

1. Doctor-Patient Relationship 

Promoting adherence in patients with epilepsy requires a solid doctor-patient bond. Building trust, keeping communication open, and encouraging a team effort may help patients manage their epilepsy better. 

2. Psychosocial Factors 

Support networks and counseling may address the mental and social factors in adherence among those with epilepsy. Peer support groups, family counseling, or mental health interventions may boost adherence and help patients deal with life. 

3. Behavioural Interventions 

Behavioural interventions like motivational interviewing, cognitive-behavioural therapy, and group therapy may help patients overcome barriers to adherence. These methods are aimed at changing beliefs and attitudes to management options and promoting self-management abilities. 

4. Educational Interventions 

In-depth epilepsy and AED education may boost adherence by empowering patients with the knowledge they need to manage their disease effectively. Education programs, online resources, and support groups all play a crucial role in enhancing understanding and promoting adherence. 

5. Mixed Interventions 

Combining behavioural and educational interventions may offer a holistic take on adherence management. It addresses both the mental and informational aspects of therapy. This integrated approach is essential in ensuring that patients are well-equipped to steer through the complex process of managing their epilepsy treatment. 

6. Medication Management Tools and Technologies 

Technology advances present chances to streamline medication management and improve adherence. Pill organizers, reminder services, and mobile apps may assist patients with dose scheduling, missed pill tracking, and easy access to information about their epilepsy treatment plan. 

Research on Adherence to Antiepileptic Therapy 

Studying adherence in those with epilepsy is key in understanding management realities and pinpointing areas of improvement.   

1. Study Designs 

Research on adherence in epilepsy focus on cross-sectional, longitudinal, or intervention-based study designs. Each of these can provide useful insights into the extent, patterns, and predictors of adherence in different patient populations. 

2. Materials and Methods 

A variety of ways are used in adherence research to measure and evaluate treatment adherence. These include self-report questionnaires, pill counts, prescription refill rates, electronic monitoring, and biomarker analysis. 

3. Results and Findings 

Several factors have been identified that affect adherence in epilepsy patients. Seizure type and frequency, medication regime, patient traits, and ideas about epilepsy and its treatment, for instance. Interventions focusing on these have shown great promise in improving patient satisfaction and adherence rates. 

4. Implications for Practice and Future Research 

It’s critical to understand what leads to non-adherence in patients with epilepsy. We need to put in motion tactics based on evidence to address these problems. This may help us achieve the best treatment outcomes. As we move forward, we’ll need more research on personalizing interventions to meet the unique needs of individual patients. This will be key in maximizing the effects of adherence management. 

Conclusion 

 In conclusion, following treatment is key in managing epilepsy well. With so many factors affecting adherence, healthcare providers have to use a range of tactics to tackle these challenges. By building strong doctor-patient relationships, providing full education, setting in motion behavioural interventions, and using medication management tools and technology, healthcare professionals may help patients have an active part in managing their epilepsy and improve their quality of life. 

Adherence to epilepsy treatment provided by the doctor is important in research and clinical practice. A wide array of factors affect patient outcomes. As we learn more about the complex factors that impact adherence, it’s crucial for healthcare providers to adapt and come up with new ways to deal with these problems and ensure optimal patient care. 

Frequently Asked Questions (FAQs) 

References: 

1. National Center for Biotechnology Information (NCBI). Adherence to Antiepileptic Therapy in Adults – PMC [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5488564 

2. National Center for Biotechnology Information (NCBI). Trajectories of adherence to airway clearance therapy for patients with cystic fibrosis [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/20304772 

3. National Center for Biotechnology Information (NCBI). Longitudinal analysis of patterns and predictors of changes in self-reported adherence to antiretroviral therapy: Swiss HIV Cohort Study [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/20035231 

4. National Center for Biotechnology Information (NCBI). Pattern of diagnostic and therapeutic care of childhood epilepsy in Alexandria, Egypt [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/12201186 

5. National Center for Biotechnology Information (NCBI). Anticonvulsant effect of diphenylhydantoin relative to plasma levels. A prospective three-year study in ambulant patients with generalized epileptic seizures [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/4212949 

6. National Center for Biotechnology Information (NCBI). A prospective study on sudden unexpected death in epilepsy [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/2774506 

7. National Center for Biotechnology Information (NCBI). Sudden and unexpected natural death in childhood and adolescence [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/4021009 

8. National Center for Biotechnology Information (NCBI). Nonadherence to antiepileptic drugs and increased mortality: findings from the RANSOM Study [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/18565827 

9. National Center for Biotechnology Information (NCBI). Prevalence and cost of nonadherence to antiepileptic drugs in elderly patients with epilepsy [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/19028602 

10. National Center for Biotechnology Information (NCBI). Meta-analysis of psychological interventions to promote adherence to treatment in pediatric chronic health conditions [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/18192300 

11. National Center for Biotechnology Information (NCBI). One-month adherence in children with new-onset epilepsy: white-coat compliance does not occur [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/18316355 

12. National Center for Biotechnology Information (NCBI). Improvement of medication compliance in uncontrolled hypertension [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/73694 

13. National Center for Biotechnology Information (NCBI). A comparison study of multiple measures of adherence to HIV protease inhibitors [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/11352698 

14. National Center for Biotechnology Information (NCBI). Compliance with appointments and medications in a pediatric neurology clinic at a University Hospital in Riyadh, Saudi Arabia [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/12235472 

15. National Center for Biotechnology Information (NCBI). Adherence to treatment in children with epilepsy: who follows “doctor’s orders”? [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/11114221 

16. National Center for Biotechnology Information (NCBI). Treatment factors affecting longitudinal quality of life in new onset pediatric epilepsy [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/21278379 

17. National Center for Biotechnology Information (NCBI). Group-based trajectory modeling in clinical research [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/20192788 

18. National Center for Biotechnology Information (NCBI). Drug compliance of children and adolescents with epilepsy [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/15978849 

19. National Center for Biotechnology Information (NCBI). Adolescent and caregiver experiences with epilepsy [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/19406756 

20. National Center for Biotechnology Information (NCBI). Compliance with health regimens of adolescents with epilepsy [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/11162760 

21. National Center for Biotechnology Information (NCBI). Development and reliability of a correction factor for parent-reported adherence to pediatric antiepileptic drug therapy [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/21087247 

22. National Center for Biotechnology Information (NCBI). Development and validation of the Pediatric Epilepsy Medication Self-Management Questionnaire [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/20452831 

23. National Center for Biotechnology Information (NCBI). Pediatric asthma: a look at adherence from the patient and family perspective [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/15462707 

24. National Center for Biotechnology Information (NCBI). Volitional and accidental nonadherence to pediatric inflammatory bowel disease treatment plans: initial investigation of associations with quality of life and disease activity [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/20498007 

25. National Center for Biotechnology Information (NCBI). Volitional nonadherence in pediatric asthma: parental report of motivating factors [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/17986372 

26. National Center for Biotechnology Information (NCBI). Barriers to treatment adherence for children with cystic fibrosis and asthma: what gets in the way? [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/16401680 

27. National Center for Biotechnology Information (NCBI). What predicts poor collection of medication among children with asthma? A case-control study [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/12503705 

28. National Center for Biotechnology Information (NCBI). Family asthma management routines: connections to medical adherence and quality of life [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/15689901 

29. National Center for Biotechnology Information (NCBI). Adolescent non-adherence: prevalence and consequences in liver transplant recipients [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/16677353 

30. National Center for Biotechnology Information (NCBI). Pediatric unintentional injury: behavioural risk factors and implications for prevention [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/17565295 

31. National Center for Biotechnology Information (NCBI). The return to smoking: 1-year relapse trajectories among female smokers [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/16085524 

32. National Center for Biotechnology Information (NCBI). Trajectories of symptoms and impairment for pediatric patients with functional abdominal pain: a 5-year longitudinal study [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/16721324 

33. National Center for Biotechnology Information (NCBI). Critical comparison of novel and existing methods of compliance assessment during a clinical trial of an oral iron chelator [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/7983239 

34. National Center for Biotechnology Information (NCBI). The Allocation of Treatment Responsibility scale: a novel tool for assessing patient and caregiver management of pediatric medical treatment regimens [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/21108707 

35. National Center for Biotechnology Information (NCBI). ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/16886973 

36. National Center for Biotechnology Information (NCBI). Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/19889013 

37. American Medical Association (AMA). Terms of Use [Internet]. [cited 2024 Mar 18]. Available from: https://www.ama-assn.org/about/terms-use 

38. American Medical Association (AMA). Privacy Policy [Internet]. [cited 2024 Mar 18]. Available from: https://www.ama-assn.org/about/privacy-policy 

39. American Medical Association (AMA). Accessibility Statement [Internet]. [cited 2024 Mar 18]. Available from: https://www.ama-assn.org/about/accessibility-statement 

40. JAMA Network. Patterns of Nonadherence to Antiepileptic Drug Therapy in Children With Newly Diagnosed Epilepsy [Internet]. [cited 2024 Mar 18]. Available from: https://jamanetwork.com/journals/jama/fullarticle/899377 

41. National Center for Biotechnology Information (NCBI). Managing patient adherence and quality of life in epilepsy – PMC [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2654533 

42. National Center for Biotechnology Information (NCBI). The impact of brief lifestyle self-management education for the control of seizures [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/30925235 

43. National Center for Biotechnology Information (NCBI). Sepulveda Epilepsy Education: the efficacy of a psychoeducational treatment program in treating medical and psychosocial aspects of epilepsy [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/2303015 

44. National Center for Biotechnology Information (NCBI). Evaluation of Kilifi epilepsy education programme: a randomized controlled trial [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/24447063 

45. National Center for Biotechnology Information (NCBI). An economic evaluation of a multicomponent self-management intervention for adults with epilepsy (ZMILE study) [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/28589669 

46. National Center for Biotechnology Information (NCBI). Enhancing medical compliance of patients with convulsive epilepsy in rural community: a randomized intervention trial [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/24117425 

47. National Center for Biotechnology Information (NCBI). Preliminary feasibility, acceptability, and efficacy of an innovative adherence intervention for children with newly diagnosed epilepsy [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/23613481 

48. National Center for Biotechnology Information (NCBI). A randomised trial of strategies to improve patient compliance with anticonvulsant therapy [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/6430689 

49. National Center for Biotechnology Information (NCBI). Compliance with drug therapy by epileptic patients [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/7084138 

50. National Center for Biotechnology Information (NCBI). Self-management education for adults with poorly controlled epilepsy (SMILE (UK)): statistical, economic and qualitative analysis plan for a randomised controlled trial [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/26068449 

51. National Center for Biotechnology Information (NCBI). Self-Management education for adults with poorly controlled epILEpsy [SMILE (UK)]: a randomised controlled trial [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/29717699 

52. National Center for Biotechnology Information (NCBI). The effectiveness of a group self-management education course for adults with poorly controlled epilepsy, SMILE (UK): A randomized controlled trial [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/29658989 

53. National Center for Biotechnology Information (NCBI). Epilepsy video animation: Impact on knowledge and drug adherence in pediatric epilepsy patients and caregivers [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/29986196 

54. National Center for Biotechnology Information (NCBI). Intervention to improve compliance with pediatric anticonvulsant therapy [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/10249191 

55. National Center for Biotechnology Information (NCBI). An evaluation of the impact of health worker and patient education on the care and compliance of patients with epilepsy in Zimbabwe [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/10219280 

56. National Center for Biotechnology Information (NCBI). Effect of Reminder Devices on Medication Adherence: The REMIND Randomized Clinical Trial [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/28241271 

57. National Center for Biotechnology Information (NCBI). Dose frequency and dose interval compliance with multiple antiepileptic medications during a controlled clinical trial [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/7588455 

58. National Center for Biotechnology Information (NCBI). Randomized trial of a program to enhance the competencies of children with epilepsy [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/2406126 

59. National Center for Biotechnology Information (NCBI). The efficacy of an educational treatment program for patients with epilepsy (MOSES): results of a controlled, randomized study. Modular Service Package Epilepsy [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/12027917 

60. National Center for Biotechnology Information (NCBI). A randomized trial of a group based cognitive behaviour therapy program for older adults with epilepsy: the impact on seizure frequency, depression and psychosocial well-being [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/20927577 

61. National Center for Biotechnology Information (NCBI). Feasibility and effects of nurse run clinics for patients with epilepsy in general practice: randomised controlled trial. Epilepsy Care Evaluation Group [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/9006472 

62. National Center for Biotechnology Information (NCBI). A home-based, primary-care model for epilepsy care in India: Basis and design [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/31168493 

63. National Center for Biotechnology Information (NCBI). Quality of life of people with epilepsy: a European study [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/9070599 

64. National Center for Biotechnology Information (NCBI). Comparison of drug adherence rates among patients with seven different medical conditions [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/18363527 

65. National Center for Biotechnology Information (NCBI). Medication compliance and persistence: terminology and definitions [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/18237359 

66. National Center for Biotechnology Information (NCBI). Increasing adherence to treatment in epilepsy: what do the strongest trials show? [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27573252 

67. National Center for Biotechnology Information (NCBI). Prevalence and cost of nonadherence with antiepileptic drugs in an adult managed care population [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/18031549 

68. National Center for Biotechnology Information (NCBI). Variations in patients’ adherence to medical recommendations: a quantitative review of 50 years of research [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/15076819 

69. National Center for Biotechnology Information (NCBI). Managing patient adherence and quality of life in epilepsy [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/19300542 

70. National Center for Biotechnology Information (NCBI). Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE) [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/15816939 

71. National Center for Biotechnology Information (NCBI). Development of a search filter to identify reports of controlled clinical trials within CINAHL Plus [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/30737884 

72. National Center for Biotechnology Information (NCBI). Measuring inconsistency in meta-analyses [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/12958120 

73. National Center for Biotechnology Information (NCBI). A systematic review of the effectiveness of interventions to help older people adhere to medication regimes [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/15082425 

74. National Center for Biotechnology Information (NCBI). The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/20156912 

75. National Center for Biotechnology Information (NCBI). Intentional and unintentional medication non-adherence: a comprehensive framework for clinical research and practice? A discussion paper [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/16973166 

76. National Center for Biotechnology Information (NCBI). A review of medication adherence in people with epilepsy [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27781263 

77. National Center for Biotechnology Information (NCBI). Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/10584742 

78. National Center for Biotechnology Information (NCBI). Incidence of epilepsy: a systematic review and meta-analysis [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/21893672 

79. National Center for Biotechnology Information (NCBI). A critical evaluation of the methodology of the literature on medication compliance [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/10369613 

80. National Center for Biotechnology Information (NCBI). Interventions for enhancing medication adherence [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/25412402 

81. National Center for Biotechnology Information (NCBI). Measures of adherence to epilepsy treatment: review of present practices and recommendations for future directions [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/18479395 

82. National Center for Biotechnology Information (NCBI). Meta-analysis of trials of interventions to improve medication adherence [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/12701547 

83. National Center for Biotechnology Information (NCBI). Ethics in adherence promotion and monitoring [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/11018582 

84. National Center for Biotechnology Information (NCBI). Effectiveness of interventions to improve patient compliance: a meta-analysis [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/9708588 

85. National Center for Biotechnology Information (NCBI). The epidemiology of epilepsy revisited [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/12644744 

86. National Center for Biotechnology Information (NCBI). Interventions to improve adherence to lipid lowering medication [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/20238331 

87. National Center for Biotechnology Information (NCBI). Informed adherence: the need for shared medical decision making [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/11018581 

88. National Center for Biotechnology Information (NCBI). Patient adherence to treatment: three decades of research. A comprehensive review [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/11679023 

89. National Center for Biotechnology Information (NCBI). Interventions for improving adherence to treatment recommendations in people with type 2 diabetes mellitus [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/15846672 

90. National Center for Biotechnology Information (NCBI). A new taxonomy for describing and defining adherence to medications [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/22486599 

91. National Center for Biotechnology Information (NCBI). Strategies for improving adherence to antiepileptic drug treatment in patients with epilepsy [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/21249705 

92. National Center for Biotechnology Information (NCBI). Strategies for improving adherence to antiepileptic drug treatment in people with epilepsy [Internet]. [cited 2024 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/28157274 

93. Cochrane Library. Strategies for improving adherence to antiepileptic drug treatment in people with epilepsy [Internet]. [cited 2024 Mar 18]. Available from: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008312.pub4/references 

94. Cochrane Library. Strategies for improving adherence to antiepileptic drug treatment in people with epilepsy [Internet]. [cited 2024 Mar 18]. Available from: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008312.pub4/full 

Disclaimer: The information provided here is for educational/awareness purposes only and is not intended to be a substitute for medical treatment by a healthcare professional and should not be relied upon to diagnose or treat any medical condition. The reader should consult a registered medical practitioner to determine the appropriateness of the information and before consuming any medication. PharmEasy does not provide any guarantee or warranty (express or implied) regarding the accuracy, adequacy, completeness, legality, reliability or usefulness of the information; and disclaims any liability arising thereof.

Links and product recommendations in the information provided here are advertisements of third-party products available on the website. PharmEasy does not make any representation on the accuracy or suitability of such products/services. Advertisements do not influence the editorial decisions or content. The information in this blog is subject to change without notice. The authors and administrators reserve the right to modify, add, or remove content without notification. It is your responsibility to review this disclaimer regularly for any changes.